Loading organizations...
Loading organizations...

Foresite Capital: Multi-stage healthcare and life sciences investment firm funding AI-powered therapeutics, devices, diagnostics, and services.
Foresite Capital is a multi-stage healthcare investment firm based in San Francisco, California, that applies scientific and data-driven approaches to fund early-stage and growth-stage businesses addressing unmet clinical needs. The firm invests across therapeutics, medical devices, diagnostics, and healthcare services, often focusing on the intersection of biology, data, and technology. Operating with a team of more than 70 employees, the organization manages approximately $3.5 billion in assets under management and recently closed its $900 million sixth fund in 2024. Its historical portfolio has achieved over 50 initial public offerings and 58 FDA approvals, featuring notable life sciences companies such as 10x Genomics, Alumis, Xaira Therapeutics, and Latigo Biotherapeutics. The firm also operates Foresite Labs, an internal incubation platform dedicated to launching artificial intelligence-driven therapeutic startups. Foresite Capital was founded in 2011 by Jim Tananbaum.
Key people at Foresite Capital.
Foresite Capital is a multi-stage healthcare and life sciences investment firm that applies a scientific, data-driven approach to invest in companies addressing significant unmet clinical needs. Its mission is to catalyze the transformation of healthcare by funding visionary businesses leveraging biology, big data, and machine intelligence to personalize healthcare and accelerate innovation. The firm invests across all stages of a company’s lifecycle, focusing on breakthrough opportunities at the intersection of technology and biotech. Its portfolio includes companies developing advanced genomics, biopharmaceuticals, and novel therapies, thereby impacting the startup ecosystem by enabling rapid growth and innovation in healthcare[1][2][3].
Founded in 2011 by Jim Tananbaum, Foresite Capital has evolved from raising its initial $100 million fund in 2013 to managing multiple funds totaling billions, with offices in Los Angeles, San Francisco, New York, and beyond. The firm is led by a team of experienced partners including Tananbaum, Vikram Bajaj, Dorothy Margolskee, Michael Rome, Dennis Ryan, and Hadi Tabbaa. Its founding vision was to combine deep scientific expertise with data science to identify and support companies that could transform healthcare through personalized medicine and advanced technologies. Early investments in companies like 10x Genomics and Eikon Therapeutics highlight pivotal moments where Foresite’s collaborative and technical approach accelerated company growth and innovation[5][2][3].
Foresite Capital rides the wave of healthcare’s transformation driven by advances in genomics, data science, and biotechnology. The timing is critical as vast biological and genetic data become accessible, enabling personalized medicine and novel therapeutic approaches. Market forces such as increasing demand for precision healthcare, regulatory support for innovation, and technological breakthroughs favor firms like Foresite that combine deep scientific insight with data-driven investment strategies. By funding companies at the intersection of tech and biotech, Foresite influences the broader ecosystem by accelerating the development of impactful medical solutions and reshaping the healthcare industry[2][6].
Looking ahead, Foresite Capital is poised to continue expanding its influence by investing in emerging technologies that further personalize and improve healthcare outcomes. Trends such as artificial intelligence in drug discovery, advanced gene editing, and integrated healthcare data platforms will likely shape its investment focus. As healthcare innovation accelerates, Foresite’s collaborative, science-driven model positions it to remain a key partner for visionary entrepreneurs, driving the next generation of transformative healthcare companies and solutions[2][6]. This ongoing commitment ties back to its mission of addressing unmet clinical needs through breakthrough science and data-driven investment.
Key people at Foresite Capital.